Département d’hématologie clinique, Inserm U1245, centre Henri Becquerel, Rouen
Optimising the evaluation of the therapeutic response is a major challenge in the management of diffuse large B-cell lymphomas. The two pillars for assessing therapeutic response are the measurement of circulating tumour DNA and the metabolic response based on PET. These non-invasive techniques, assessing molecular and metabolic minimal residual disease, can be combined and repeated at key times in the therapeutic phases, mainly after two and four cycles of immunochemotherapy, during the first line of treatment. An adaptive prognostic model combining the international prognostic index and metabolic and molecular minimal residual disease status seems relevant. However, this requires standardisation of response criteria and validation of its usefulness in Phase III trials.